Global Information
회사소개 | 문의
SALE

고혈압 : 주요 19개국 시장 예측

Epiomic Epidemiology Series: Hypertension Forecast in 19 Major Markets 2018-2028

리서치사 Black Swan Analysis
발행일 2018년 08월 상품 코드 403740
페이지 정보 영문 70 Pages
가격
US $ 5,800 US $ 5,104 ₩ 5,800,000 PDF by E-mail (Single User License)
US $ 8,700 US $ 7,656 ₩ 8,700,000 PDF by E-mail (Site License)
US $ 10,400 US $ 9,152 ₩ 10,400,000 PDF by E-mail (Global License)


고혈압 : 주요 19개국 시장 예측 Epiomic Epidemiology Series: Hypertension Forecast in 19 Major Markets 2018-2028
발행일 : 2018년 08월 페이지 정보 : 영문 70 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

고혈압은 상당히 일반적인 질환의 일종으로, 동맥 벽면에 대한 혈액의 압력이 너무 높기 때문에 다양한 건강상 문제(심장발작, 뇌졸중, 만성 신장질환, 심부전 등)이 발생한다는 특징이 있습니다.

세계 주요 19개국의 고혈압(Hypertension) 발증 상황을 분석했으며, 질환 개요, 현재 환자수, 성별·연대별(5세 단위) 상황, 지역별·민족별 동향, 위험인자, 질환의 진단과 예후, 주요 증상과 합병증, 향후 동향 전망(향후 10년간) 등의 정보를 정리하여 전해드립니다.

목차

  • 서론
  • 질환의 원인
  • 위험인자와 예방법
  • 질환의 진단
  • 지역별/민족별 차이
  • 질환의 예후와 임상 경과
  • 질환에 관련된 주요 공존증/특징
  • 환자수 정량화 방법
  • 고혈압 최대 환자수
  • 고혈압 환자의 특징
    • 고혈압 공존증
  • 약어 리스트
  • 참고 문헌
  • 부록

분석 대상국

  • 미국, 캐나다, 프랑스, 독일, 이탈리아, 스페인, 영국, 폴란드, 네덜란드, 러시아, 터키, 일본, 중국, 한국, 인도, 호주, 브라질, 멕시코, 아르헨티나
LSH 18.08.01

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hypertension in 19 Major Markets

Hypertension (high blood pressure) is a common condition in which the force of the blood against the artery walls is high enough that it may eventually cause serious health problems. These health problems include heart attack, stroke, chronic kidney disease and heart failure.

This report provides the current prevalent population for Hypertension across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Hypertension have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Hypertension include:

Chronic heart failure

Chronic kidney disease

Myocardial infarction

Ischaemic heart disease

Stroke

Diabetes

Metabolic syndrome

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global Hypertension market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of Hypertension and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Better understanding on the impact of specific co-morbid conditions on the prevalent population of Hypertension patients.

Identification of Hypertension patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of Hypertension patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR HYPERTENSION
  • FEATURES OF HYPERTENSION PATIENTS
  • COMORBIDITIES OF HYPERTENSION PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Classification of hypertension
  • Table 2. Prevalence of hypertension, total (000s)
  • Table 3. Prevalence of hypertension, males (000s)
  • Table 4. Prevalence of hypertension, females (000s)
  • Table 5. Patients with hypertension by control status, total (000s)
  • Table 6. Diagnosed/Aware hypertension patients, total (000s)
  • Table 7. Patients with hypertension by BMI status, total (000s)
  • Table 8. Patients with hypertension by kidney function, total (000s)
  • Table 9. Hypertension patients with diabetes, total (000s)
  • Table 10. Hypertension patients with chronic heart failure, total (000s)
  • Table 11. Hypertension patients with coronary artery disease, total (000s)
  • Table 12. Hypertension patients with peripheral artery disease, total (000s)
  • Table 13. Hypertension patients with dyslipidaemia, total (000s)
  • Table 14. Hypertension patients with elevated CRP, total (000s)
  • Table 15. Hypertension patients with metabolic syndrome, total (000s)
  • Table 16. Hypertension patients with retinopathy, total (000s)
  • Table 17. Hypertension patients with atrial fibrillation, total (000s)
  • Table 18. Abbreviations and acronyms used in the report
  • Table 19. USA prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 20. USA prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 21. Canada prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 22. Canada prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 23. France prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 24. France prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 25. Germany prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 26. Germany prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 27. Italy prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 28. Italy prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 29. Spain prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 30. Spain prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 31. UK prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 32. UK prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 33. Poland prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 34. Poland prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 35. Netherlands prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 36. Netherlands prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 37. Russia prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 38. Russia prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 39. Turkey prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 40. Turkey prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 41. Japan prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 42. Japan prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 43. China prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 44. China prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 45. South Korea prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 46. South Korea prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 47. India prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 48. India prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 49. Australia prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 50. Australia prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 51. Brazil prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 52. Brazil prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 53. Mexico prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 54. Mexico prevalence of hypertension by 5-yr age cohort, females (000s)
  • Table 55. Argentina prevalence of hypertension by 5-yr age cohort, males (000s)
  • Table 56. Argentina prevalence of hypertension by 5-yr age cohort, females (000s)
Back to Top
전화 문의
이용안내
 
BCC Research